Business
Aura Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights
Positive Phase 1 Trial Data in Non-Muscle Invasive Bladder Cancer (NMIBC) Presented at the 40th Annual European Association of Urology Congress; Supports Front-Line Treatment Potential Clinical Pipeline Continues to Advance with Phase 3 CoMpass Trial Actively Enrolling Phase 2 Trial in Metastases to the Choroid Initiated Cash Position Expected to Support Operations into 2H 2026 BOSTON, Mass., March 24, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology
About this update from Aura Biosciences, Inc.
[{"type":"image","alt":"Aura Biosciences, Inc.","displaySize":"","headline":null,"caption":"Aura Biosciences, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":76,"url":"https://media.zenfs.com/en/globenewswire.com/2592eb91327180eb73f99563eef568ed"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/gFIc2.J2rzI4RhAQ9QXMDQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEwNjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/2592eb91327180eb73f99563eef568ed","width":300,"height":76}},"lazy":false},{"type":"text","content":"Positive Phase 1 Trial Data in Non-Muscle Invasive Bladder Cancer (NMIBC) Presented at the 40th Annual European Association of Urology Congress; Supports Front-Line Treatment Potential","length":184,"tagName":"p"},{"type":"text","content":"Clinical Pipeline Continues to Advance with Phase 3 CoMpass Trial Actively Enrolling","length":84,"tagName":"p"},{"type":"text","content":"Phase 2 Trial in Metastases to the Choroid Initiated","length":52,"tagName":"p"},{"type":"text","content":"Cash Position Expected to Support Operations into 2H 2026","length":57,"tagName":"p"},{"type":"text","content":"BOSTON, Mass., March 24, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today reported financial results for the fourth quarter and year ended December 31, 2024, and provided recent business highlights.","length":343,"tagName":"p"},{"type":"text","content":"“We believe that bel-sar has the potential to transform the treatment paradigm in multiple rare oncology indications starting with ocular cancers and more broadly across many solid tumors such as bladder cancer. The data presented from the Phase 2 trial in early-stage choroidal melanoma and the Phase 1 trial in NMIBC demonstrated bel-sar’s potential as a front-line treatment option across multiple tumor types,” said Elisabet de los Pinos, Chief Executive Officer of Aura Biosciences. “These data highlight the potential clinical benefit of a novel dual mechanism of action driven by highly targeted cytotoxicity and robust cell-mediated immunity. We look forward to continuing to advance our pipeline across multiple indications with high unmet patient need.”","length":763,"tagName":"p"},{"type":"text","content":"Recent Pipeline Deve...